The rationale for using anti-TNF drugs in rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and psoriasis centered on clinical and experimental data linking pro-inflammatory activities of TNF to non-resolving inflammation. This evidence concerns the gene TNF and rheumatoid arthritis.